Skip to main content
Intro to ILD (Part I): the essentials

🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical app

Dr. John Cush RheumNow

9 months ago
Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/Fn76PiGsPl Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/JpyE3T7Atj
APP Pearls “Do not order a test if you do not know how to interpret the results whether normal or abnormal” - Madiso

Dr. John Cush RheumNow

9 months ago

APP Pearls “Do not order a test if you do not know how to interpret the results whether normal or abnormal” - Madison Chastain, CRNP

Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositi

Dr. John Cush RheumNow

9 months ago
Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/M80026Z3Ur
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.
Current guidelines recommend limiting the use of glucocorticoids by coining the new concept of “bridging therapy”, that is, use GCs when the disease is active and get rid of them as soon as you can. This way of thinking is conceptually attractive, however, the formula for translation to real life settings is not included.
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook os

Dr. John Cush RheumNow

9 months 1 week ago
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/ICSDysexOR
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1R

Dr. John Cush RheumNow

9 months 1 week ago
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/01o05qYPjU https://t.co/M02xrvxKre
APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC

Dr. John Cush RheumNow

9 months 1 week ago
APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis

The FDA has approved nerandomilast (Jascayd), a PDE4b in

Dr. John Cush RheumNow

9 months 1 week ago
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/G2SS0qJTfl
Three Things to Know About Hiring, Onboarding, and Training APPs

As the utilization of APPs (nurse practitioners and p

Dr. John Cush RheumNow

9 months 1 week ago
Three Things to Know About Hiring, Onboarding, and Training APPs As the utilization of APPs (nurse practitioners and physician assistants) in rheumatology becomes more prevalent, here are three things to consider if you are thinking about adding an APP to your practice: Read https://t.co/24RVd09vcK
A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal threshold of 50,000 cells/mm3.
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
Lupus Guidelines 2025
Telling You Where to Go (12.19.2025)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNo

Dr. John Cush RheumNow

9 months 1 week ago
Telling You Where to Go (12.19.2025) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients? https://t.co/bwF89L9Z7R
×